Linzess
Drug - Linzess [Forest Labrotories, Inc.]
June 2013
Therapeutic area - Gastrointestinal Agent
Approval criteria (gender specific)
- Male age 18 years of age or older AND
- Diagnosis of Irritable-Bowel Syndrome with constipation or chronic idiopathic constipation AND
- Documentation that constipation-causing therapies for other diseases have been reviewed and therapies avoided if possible AND
- Patient has tried and failed at least 4 of the following medical therapies: psyllium, methlycellulose, polycarbophil, wheat dexdrin, magnesium hydoxide, magnesium citrate, sodium phosphate, lactulose, PEG electrolyte solution, docusate, mineral oil, senna, bisacodyl, phosphate enema, mineral oil retention, tap-water enema, glycerin-bisacodyl suppository
- Female age 18 years of age or older AND
- Diagnosis of Irritable-Bowel Syndrome with constipation or chronic idiopathic constipation AND
- Documentation that constipation-causing therapies for other diseases have been reviewed and avoided if possible AND
- Patient has tried and failed at least 4 of the following medical therapies: psyllium, methlycellulose, polycarbophil, wheat dexdrin, magnesium hydoxide, magnesium citrate, sodium phosphate, lactulose, PEG electrolyte solution, docusate, mineral oil, senna, bisacodyl, phosphate enema, mineral oil retention, tap-water enema, glycerin-bisacodyl suppository AND
- Patient has tried and failed Amitiza
Quantity limit
34 capsules per 34 days
Background information
LINZESS is a guanylate cyclase-C agonist indicated in adults for treatment of: Irritable bowel syndrome with constipation (IBS-C).
Chronic idiopathic constipation.
Questions?
MHCP Provider Call Center 651-431-2700 or 800-366-5411
